GENFIT CORP.
245 First Street - 18th Floor
Suite 1806
Cambridge
Massachusetts
02142
United States
Tel: 617-444-8416
Fax: 617- 444-8405
Website: http://www.genfit.com/
Email: Karen.Miller@Genfit.com
About GENFIT CORP.
Genfit is a biopharmaceutical company, listed on Alternext by Euronext™ Paris (ALGFT - FR0004163111) with headquarters in Lille, France and a US subsidiary in Cambridge, Massachusetts.Through its world-renowned scientific expertise, particularly in the field of nuclear receptors, Genfit’s research efforts are focused on the discovery and development of new treatments mainly in the growing therapeutic areas of Cardiometabolic and Neurodegenerative disorders, such as prediabetes/diabetes, atherosclerosis, dyslipidemia, obesity, and Alzheimer’s. Genfit uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments to address these major public health problems and their unmet medical needs.
Genfit has an original business model built on both proprietary internal programs and a strong track record of partner-supported programs and collaborations. This strategy allows the company to efficiently manage the risks associated with the internal programs, and at the same time build value for its shareholders. Genfit, on its own or in collaboration with its major pharmaceutical partners, has thus created a rich and diversified pipeline of drug candidates in pre-clinical and clinical development, as well as a broad intellectual property portfolio.
Genfit’s strong portfolio of therapeutic products, tools, and clinical biomarkers, together with its scientific expertise, have made the Company into a European biotechnology leader.
GENFIT
Parc Eurasanté – Lille Metropole
885 Avenue Eugene Avinee
59120 Loos
France
Tel : +33 (0)3 2016 4000
Fax : +33 (0)3 2016 4001
202 articles with GENFIT CORP.
-
GENFIT Reports First Quarter 2022 Financial Information (Unaudited financial information under IFRS)
5/11/2022
GENFIT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, announced its cash position as of March 31, 2022 and revenues for the first three months of 2022.
-
GENFIT Announces Publication of the 2021 Universal Registration Document; the 2021 Annual Report on Form 20-F and Availability of Preparatory Documents for the Annual Combined Shareholders Meeting on May 25, 2022
4/29/2022
GENFIT announced the filing of its 2021 Universal Registration Document with the Autorité des marchés financiers and its Annual Report on Form 20-F for the year ended December 31, 2021 with the U.S. Securities and Exchange Commission, as well as the availability of preparatory documents for its annual shareholders meeting on Wednesday May 25, 2022.
-
GENFIT Annual Combined General Meeting of May 25, 2022 — Availability of Preparatory Documents
4/20/2022
GENFIT announced that it published in the April 20, 2022 French legal announcements bulletin n°47 its convening notice that the Combined Shareholders Meeting will be held on May 25, 2022, at 10:00am, at the Faculty of Pharmaceutical Sciences in Lille, located at Parc Eurasanté, 3 rue du Professeur Laguesse, 59000 Lille, France.
-
GENFIT delivered on its promise to improve its financial situation in the year to December 31, 2021, posting an income of $40.8 million USD from a loss of $20.3 million in the year prior.
-
GENFIT Reports Full-Year 2021 Financial Results and Provides Corporate Update
4/7/2022
GENFIT announced annual financial results for the year ended December 31, 2021.
-
GENFIT Announces Solid Revenues and Cash Position as of December 31, 2021
2/28/2022
GENFIT announced its cash position as of December 31, 2021 and revenues for 20211.
-
GENFIT: 2022 Financial Calendar
1/24/2022
GENFIT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, announced its provisional financial calendar for 2022.
-
Ipsen and GENFIT Enter Into Exclusive Licensing Agreement for Elafibranor, a Phase III Asset Evaluated in Primary Biliary Cholangitis, as Part of a Long-Term Global Partnership
12/17/2021
Ipsen and GENFIT have entered into a long-term strategic partnership for global collaboration between the two companies.
-
On heels of global strategic partnership announced today, GENFIT acquires rights to novel asset
12/17/2021
GENFIT is pleased to announce the strengthening of its cholestatic disease franchise through the acquisition of exclusive rights from Genoscience Pharma to develop and commercialize the investigational treatment GNS561 in cholangiocarcinoma in the United States, Canada and Europe, including the United Kingdom and Switzerland.
-
GENFIT: Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership
12/17/2021
Ipsen and GENFIT, have entered into a long-term strategic partnership for global collaboration between the two companies.
-
GENFIT: FNIH NIMBLE Study Demonstrates NIS4® Technology’s Unique Performance in Identifying Patients with “at-risk” NASH
11/18/2021
GENFIT is proud to announce that NIS4® technology’s utility has been recognized in a Stage 1 study1 undertaken by the Non-Invasive Biomarkers of Metabolic Liver Disease initiative of the Foundation for the National Institutes of Health’s Biomarkers Consortium as demonstrating a unique performance in identifying patients with “at-risk” Non-Alcoholic Steatohepatitis.
-
GENFIT Announces First Patient First Visit for the Evaluation of NTZ in Subjects with Hepatic Impairment as part of its ACLF Program
11/9/2021
Lille, France; Cambridge, MA; November 09, 2021 - GENFIT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, announced the first patient first visit for the evaluation of NTZ in subjects with hepatic impairment as part of its ACLF program.
-
GENFIT: Third Quarter 2021 Financial Information
11/8/2021
Lille, France; Cambridge, MA; November 8, 2021 - GENFIT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, announced its cash position as of September 30, 2021 and revenues for the first nine months of 20211.
-
Instead of continuing to develop the two different assets, EDP-305 and EDP-297, the company intends to seek an out-licensing deal to focus on infectious respiratory diseases.
-
GENFIT Reports First Half-Year 2021 Financial Results and Provides Corporate Update
9/29/2021
GENFIT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, announced its first half-year financial results and provided a corporate update.
-
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
7/9/2021
Lille, France; Cambridge, MA; July09, 2021 - GENFIT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, announced the half-year report of the liquidity contract with Crédit Industriel et Commercial.
-
GENFIT: June 30, 2021 Annual Shareholders Meeting results
6/30/2021
GENFIT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, announced the results of the voting by shareholders at the Combined Shareholders Meeting which took place on June 30, 2021 behind closed doors at the Company’s headquarters.
-
GENFIT obtains non-dilutive financing of €11 million in the form of a State Guaranteed Loan
6/24/2021
GENFIT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, announced the securing of a €11 million non-dilutive loan guaranteed by the French government.
-
GENFIT: June 15, 2021 Combined Shareholders Meeting: Wide support for the resolutions submitted to the shareholders’ vote but quorum not met on first convening
6/15/2021
GENFIT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, announced that the June 15, 2021 Combined Shareholders Meeting obtained a wide support for the resolutions submitted to the shareholders vote, however, quorum was not met on first convening.
-
GENFIT Informs its Shareholders of Certain Procedures for the Combined General Meeting of June 15, 2021
5/27/2021
GENFIT informs its shareholders of certain participation and organization procedures for the ordinary and extraordinary general meeting of June 15, 2021 in accordance with decree n°2021-255 of March 9, 2021, extending the application of measures of ordinance n°2020-321 of March 25, 2020 and its application decree n°2020-418 of April 10, 2020 which was extended until July 31, 2021 by the decree n°2021-255 of March 9, 2021.